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ABSTRACT
Objective: We sought to determine the role of mean platelet volume (MPV) for predicting long-term outcomes of elective percutaneous coro-
nary intervention (PCI).
Methods: On the basis of retrospective cohort study, we collected characteristics of 680 patients undergoing elective PCI from October 2005 to 
August 2010. The patients who had preoperative MPV were assessed for developing major adverse cardiac events (MACE) during 1-year fol-
low-up. They were categorized into two groups including MPV <9.6 fL (n=89) and MPV ≥9.6 fL (n=92). Data were analyzed using t-test, chi-square 
test, Pearson correlation, receiver operating characteristic (ROC) curve and logistic regression.
Results: One-hundred eighty one patients (26.6%) met inclusion criteria. The MACE was observed in 29 patients (16%); and its rate in low- and 
high-MPV groups was 11.2% and 20.7%, respectively (p=0.084). MPV was significantly higher in the patients with left ventricular ejection frac-
tion (LVEF) <40% compared with that of ≥40% (p<0.001). There were a significant and negative correlation between MPV and platelet count 
(r=-0.305, p<0.001), and significant and positive correlations between MPV and platelet distribution width (PDW) and platelet large cell ratio 
(P-LCR) (r=0.615, p<0.001 and r=0.913, p<0.001; respectively). The best MPV cut-off point was 9.25 fL; the sensitivity and specificity were 79% 
and 38%, respectively. Elevated MPV was the best predictor of MACE at 1-year follow-up (OR=11.359, 95% CI 2.481-51.994, p=0.002).
Conclusion: The results indicate that preoperative MPV is an independent predictor of the MACE at 1-year follow-up in the patients undergoing 
elective PCI. Moreover, it may be useful for risk stratification in such cases. (Anatolian J Cardiol 2015; 15: 25-30)
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Introduction
Since the percutaneous coronary intervention (PCI) has 
been introduced, restenosis and major adverse cardiac events 
(MACE) after performing PCI have been apparently reported (1, 2). 
By innovation in antiplatelet therapy, dual antiplatelet treatment, 
the rate of these complications has decreased; however, the 
number of these adverse events has been remained high leading 
to increase in concerns regarding this issue (2).
The platelets are derived from megakaryocytes in the bone 
marrow and completely are necessary for hemostasis. Also, 
some mediators produced by platelets are essential in coagu-
lation, inflammation, atherothrombotic events as well as ath-
erosclerosis which have been identified in the previous inves-
tigations (3, 4). Although the platelet volume is determined by 
the size of fragmented megakaryocyte, other factors including 
cytokines, growth factors and endothelial dysfunction may 
impact on its volume and subsequent reactivity. The larger 
platelets have more granules and consequent greater effica-
cious vasomotor, pro-inflammatory and haemostatic function 
that may lead to more cardiovascular events (5). Mean platelet 
volume (MPV) is an index for assessing the platelet activity 
measured as a component of the complete blood count. 
Recent studies have previously demonstrated correlation 
between MPV and cardiovascular morbidities and mortality 
(6). Notably, a high MPV value has been observed in patients 
with cardiovascular risk factors including diabetes mellitus, 
hypertension, hypercholesterolemia, smoking and obesity 
(6-8). Furthermore, it has been shown the diagnostic role of 
MPV, based on being inflammatory marker, in the patients with 
Behçet’s disease and malignancy (9, 10). In addition, the prog-
nostic value of MPV for predicting long-term mortality after 
PCI has been demonstrated (11).
Some of the investigations have previously shown that a cor-
relation exists between increased platelet indices before PCI 
and the rate of MACE (12-14). All the mentioned studies investi-
gated on the cohort of patients undergoing elective and urgent 
PCI rather than elective one alone, and also some findings 
showed the lack of correlation between increased baseline 
MPV and PCI outcomes. Hence, we sought to determine the cor-
relation between MPV value before purely elective PCI and the 
occurrence of defined MACE as a composite of end-points 
including long-standing cardiac care unit (CCU) hospitalization 
postoperatively, target vessel revascularization (TVR), myocar-
dial infarction (MI), stroke and death, and consequently, all 
patients were followed for a 1-year period in terms of the inci-
dence of MACE.
Methods
Study design
This study was a retrospective cohort study. We collected 
the baseline clinical and PCI characteristics of six-hundred 
eighty patients who were intervened at Taleghani hospital cath-
eterization laboratory from October 2005 until August 2010 in the 
West-Azerbaijan, Iran. This study was approved by our local 
Ethical Committee in the Urmia University of Medical Sciences.
The study cohort included the patients who had the history 
of previous acute coronary syndrome (ACS) and had already 
been scheduled to undergo purely elective PCI. After collecting 
data from registry, all patients who had the measurements of 
platelet indices including platelet count, MPV, platelet large cell 
ratio (P-LCR) and platelet distribution width (PDW) before inter-
vention were assessed in terms of the occurring pre-defined 
MACE during 1-year follow-up period. The patients were exclud-
ed if: (1) had undergone primary PCI; (2) laboratory measure-
ments were not available; (3) PCI had been failed; (4) renal insuf-
ficiency (creatinine ≥1.5 mg/dL); (5) having fever before inter-
vention; (6) the history of malignancies; and (7) the history of 
rheumatic diseases.
Before intervention, patients pretreated with aspirin 325 mg, 
clopidogrel loading 300 mg and weight adjusted intravenous 
unfractionated heparin. The goal of stenting was full lesion cov-
erage even with one or more stents. The selection of size and 
type of stent were based on operators’ decision. Patients were 
discharged on clopidogrel 75 mg/d/month for 1 year, aspirin 325 
mg/d/month at least 3 months and 80 mg/d/month of aspirin for 
an indefinite period after PCI.
Based on our institution policy, the blood samples had 
been taken from all patients 6 to 24 hours before PCI perform-
ing to measure the routine complete blood count. The sam-
ples had been collected into tubes containing EDTA and were 
analyzed using automated cell analyzer, Sysmex KX21-N, Kobe, 
Japan.
Clinical outcomes and definitions
A total of 181 patients were accordingly fulfilled inclusion 
criteria. The end-points of long-standing CCU admission, TVR, 
MI, stroke and death were considered as composite end-points 
(MACE). All outcomes were provided by either telephone inter-
views or registry data at 1-year follow-up duration. If the 
patients had been hospitalized for a cardiac complaint, we were 
concisely obtained detailed clinical data concerning the diagno-
sis and revascularization of targeted vessel.
The MI was defined as ischemic symptoms including chest 
pain more than 20 minutes with ST-segments elevation in ≥2 
contiguous leads and/or the elevation of cardiac biomarkers 
(creatine kinase MB isoenzyme and Troponin I) to >two-fold the 
upper limit of normal value. This definition had been used for 
detecting MI periprocedural and during the follow-up period. 
The long-standing CCU admission was defined as patients who 
were hospitalized more than 48 hours in the CCU ward following 
intervention due to three main reasons including recurrent rest-
ing chest pain, the dynamic alteration of electrocardiogram 
without elevation of the cardiac biomarkers and hemodynamic 
instability. Furthermore, TVR was accepted as repeated PCI or 
coronary artery bypass graft surgery (CABG) on the vessel inter-
vened previously in our center. Because the patients had not 
been undergone control angiography at follow-up period, we 
could not differentiate between restenosis, stent thrombosis or 
new lesion developing.
The drug histories were considered as medications those 
had been consumed at least one day before admission for coro-
nary intervention. All medical histories were obtained from 
patients folder. Hypertension was defined as those who had 
blood pressure above 140/90 mm Hg and/or taking antihyperten-
sive drugs (15). Diabetes mellitus was diagnosed as those having 
one of these criteria; 1) The classic symptoms of diabetes plus 
plasma glucose concentration >200 mg/dL; 2) fasting plasma 
glucose ≥126 mg/dL; 3) 2-hour post load glucose ≥200 mg/dL 
during an OGTT; and/or 4) taking anti-diabetic medicines (16). 
The familial history of coronary artery disease (CAD) was diag-
nosed as patients had a first degree male relative or a female 
relative less than 55 and 65 years old with CAD, respectively (17).
Statistical analysis
Based on our hypothesis that the elevated MPV value is asso-
ciated with poor prognosis, all patients were categorized into two 
groups. According to the median MPV value of entire cohort, the 
MPV groups included low-MPV (MPV <9.6 fL) and high-MPV 
(MPV ≥9.6 fL). Continues and categorical variables were analyzed 
using t-test and chi-square test, respectively. Correlation between 
two continues variables were calculated by the Pearson coeffi-
cient correlation. A receiver operating characteristic (ROC) curve 
was constructed to determine the area under the curve (AUC), 
sensitivity and specificity of baseline MPV value for predicting 
MACE incidence during 1-year follow-up.
Furthermore, a logistic regression model was used to identify 
the predictors of combined MACE. All measured outcomes 
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including long-standing cardiac care unit CCU hospitalization, 
TVR, MI, stroke and death were defined as composite end-
points. The covariates included age; gender; BMI (body mass 
index); the history of diabetes mellitus, hypertension, smoking, 
the positive familial history of CAD and dyslipidemia; LVEF 
before procedure; intervened vessels; and laboratory measure-
ments including PDW, P-LCR, platelet count, MPV, creatinine 
and hematocrit. The Hosmer-Lemeshow test was also used for 
goodness of fit for logistic regression.
All analyses were performed using SPSS version of 16.0 
(SPSS Inc., Chicago, IL, USA). The p value of less than 0.05 was 
considered statistically significant and the odds ratios (ORs) 
were reported with the 95% confidence intervals (CIs).
Results
Relationship between MPV and clinical characteristics
Of 680 patients who underwent PCI from October 2005 to 
August 2010, 181 patients (26.6%) met inclusion criteria. The 
patients’ mean age was 58.2±10.9 years and 124 of those were 
male (p=0.148). The MPV was categorized as follows: (1) low-
MPV, MPV <9.6 fL (n=89); (2) high-MPV, MPV ≥9.6 fL (n=92). 
Baseline clinical characteristics were depicted in Table 1.
Relationship between MPV and MACE
After division of patients based on MPV value, those charac-
teristics and the incidence of MACE were analyzed. During 
1-year follow-up period, the MACE incidence, as composite end-
points, were observed in 29 patients (16%); MI, long-standing 
CCU, TVR and death were occurred in 4, 18, 6 and 1 patients, 
respectively. Its rate in the low- and high-MPV groups was 10 
(11.2%) and 19 (20.7%), respectively; and it was no significantly 
different (p=0.084), although in the high-MPV group it was 
nearly twice as many patients as the low-MPV group.
Relationship between MPV and subgroups by risk factors
A trend was seen for the patients in the high-MPV group to 
have more number of positive familial history of CAD than the 
other group (p=0.071). The number of patients with LVEF <40% in 
the high-MPV was more than that of low-MPV group (p=0.015). 
In terms of the mean of MPV level between subgroups stratified 
by gender, cardiovascular risk factors, drug histories, and LVEF; 
analyses only showed significant difference between LVEF sub-
groups (9.5±0.8 versus 10±0.9 fL), but others did not so (Fig. 1). 
Additionally, the rate of MACE in the above mentioned subgroups 
were not significantly different.
Correlations between platelet indices
There was a significant and negative correlation between 
MPV and platelet count (r=0.305, p<0.001). Strong positive cor-
relations were also observed between MPV and PDW and 
P-LCR that were statistically significant (r=0.615, p<0.001 and 
r=0.913, p<0.001; respectively). Any other correlations were not 
observed between MPV and laboratory measurements (Table 2).
Diagnostic and prognostic values of MPV
ROC curve of MPV when predicting MACE was constructed. 
The AUC was 0.555 with 95% CI of 0.441-0.669 (p=0.347). The best 
MPV cut-off point for identifying MACE at follow-up was 9.25 fL; the 
sensitivity and specificity were 79% and 38%, respectively (Fig. 2).
The logistic regression model demonstrated that the high-
MPV, MPV ≥9.6 fL, (OR=11.359, 95% CI 2.481-51.994, p=0.002) had 
the strongest association with the incidence of MACE at 1-year 
Figure 1. Mean platelet volume between groups by left ventricular 
ejection fraction (LVEF) was significantly different
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Figure 2. ROC curve showing diagnostic value of MPV for detecting 
PCI outcomes during 1-year follow-up period
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 Total Low-MPV* High-MPV* 
 (n=181) (n=89) (n=92) P **
Age, years 58.2±10.9 57.7±10.6 58.7±11.4 0.495
Sex    0.108
Male 124 (68.5) 66 (74.2) 58 (63.0)
Female 57 (31.5) 23 (25.8) 34 (37)
Body mass index 27.4±4.4 27.5±4.4 27.2±4.4 0.670
MACE incidence 29 (16) 10 (11.2) 19 (20.7) 0.084
Prior myocardial infarction 71 (39.2) 34 (38.2) 37 (40.2) 0.781
Prior PCI 33 (18.2) 17 (19.1) 16 (17.4) 0.766
Diabetes mellitus 30 (16.6) 13 (14.6) 17 (18.5) 0.484
Dyslipidemia 87 (48.1) 46 (51.7) 41 (44.6) 0.338
Hypertension 89 (49.2) 48 (53.9) 41 (44.6) 0.208
Prior cerebrovascular events 3 (1.66) 0 (0) 3 (3.3) 0.086
Smoking 81 (44.8) 35 (39.3) 46 (50.0) 0.149
Familial history of CAD 54 (29.8) 21 (23.6) 33 (35.9) 0.071
LVEF, %    0.015
≥40% 125 (69.1) 69 (77.5) 56 (60.9)
<40% 56 (30.1) 20 (22.5) 36 (39.1)
Intervened vessel
LAD 101 (52.9) 52 (51.5) 49 (48.5) 0.484
RCA 63 (31.6) 28 (44.4) 35 (55.6) 0.353
LCX 35 (17.6) 15 (42.9) 20 (57.1) 0.405
Drug history
β-blocker 134 (74) 68 (76.4) 66 (71.7) 0.474
Statins 103 (56.9) 49 (55.1) 54 (58.7) 0.621
Aspirin 63 (34.8) 32 (36.0) 31 (33.7) 0.094
Dual antiplatelet 72 (39.8) 30 (33.7) 42 (45.7) 0.101
Serum measurements
Platelet count, 109/L 209±56.9 225±56.4 194±53.1 <0.001
PDW, fL 12.8±2.7 11.6±2.7 13.9±2.3 <0.001
P-LCR, % 23.7±7.3 18.2±3.8 29.0±5.8 <0.001
Cholesterol, mg/dL 157.5±34.2 160.6±34.3 154.4±34.0 0.218
Triglyceride, mg/dL 172.6±87.7 175.3±91.0 170.1±84.8 0.695
LDL, mg/dL 86.7±25.0 88.2±25.4 85.2±24.7 0.412
HDL, mg/dL 40.6±9.1 41.8±8.3 39.5±9.8 0.091
Hematocrit, % 39.3±5.6 38.8±5.8 39.7±5.4 0.299
ALT, mg/dL 31±36 28.9±21.9 33.2±45.9 0.297
AST, mg/dL 24.9±22.4 23.1±13.1 26.6±28.7 0.431
Creatinine, mg/dL 0.9±0.5 0.9±0.4 0.9±0.6 0.778
Values are presented as mean±SD and number (%) 
* MPV level was considered as low-MPV <9.6 fL and high-MPV ≥9.6 fL 
**Chi-square and t-test were used 
ALT - alanine aminotransferase; AST - aspartate aminotransferase; CAD - coronary artery disease; HDL - high density lipoprotein; LAD - left anterior descending artery; LCX - left 
circumflex artery; LDL - low density lipoprotein; LVEF - left ventricular ejection fraction; MACE - major adverse cardiac event; MPV - mean platelet volume; PCI - percutaneous 
coronary intervention; PDW - platelet distribution width, P-LCR - platelet large-cell ratio, RCA - right coronary artery
Table 1. Baseline clinical and procedural characteristics
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follow-up (Table 3). The Hosmer-Lemeshow test showed the 
high predictive value with p-value of 0.265.
Discussion
Based on the present investigation, the rate of MACE in high-
MPV group was about two-fold of that in low-MPV group, and the 
pre-procedural elevated MPV was an independent predictor of 
combined MACE at 1-year follow-up period in the patients who 
underwent elective PCI. Furthermore, the MPV level was inverse-
ly associated with platelet count and directly with PDW and 
P-LCR values as other biomarkers indicating platelet activity.
Platelets are one of the blood cells that have an important 
role in atherothrombosis, thrombogenesis and atherosclerotic 
lesion rupture. MPV is a simple and easily available test evaluat-
ing platelet activity and can be used as a platelet monitoring tool 
(4). Patients undergoing PCI are at the higher risk of plaque 
rupture and arterial wall injuries. These can result in platelet 
activation and consequent increased procoagulant activity and 
inflammatory processes (18).
Many previous studies have shown that the pre-procedural 
elevated MPV is associated with the incidence of MACE and 
restenosis following PCI. Yang et al. (1) investigated the role of 
MPV as a prognostic factor for restenosis. They found that it 
may be considered as a potential marker of restenosis after PCI. 
Thus patients undergoing PCI with high pre-procedural MPV 
might benefit from a high-dose antiplatelet therapy after coro-
nary intervention. Another study conducted by Huczek et al. (19) 
noted that MPV predicts angiographic reperfusion and 6-month 
mortality after primary PCI. Moreover, concerning correlation 
between MPV and cardiovascular risk factors, it was founded 
that it was at higher level in patients with history of cardiovas-
cular risk factors including smoking and diabetes (7, 8).
Some investigations were conducted regarding the correla-
tion between platelet size and PCI outcomes. Goncalves and 
coworkers (14), in terms of MPV effect on PCI outcomes at 
1-year follow-up, demonstrated that the pre-procedural MPV 
was the strong predictor of long-term adverse events. MPV 
value had prognostic value similar to troponin in the patients 
with ACS. Consequently, they concluded that MPV value can be 
considered as a marker for evaluating antiplatelet therapy after 
coronary intervention. The newly published investigation by 
Shah et al. (13) showed that there is not any correlation 
between baseline MPV and PCI outcomes. However, the mor-
tality rate was greater in patients with increased MPV over the 
follow-up compared to those without MPV change or decrease 
in its value. They entered all patients who underwent elective 
or urgent PCI and did no differentiate between those in their 
analysis. Choi and coworkers (12) were also demonstrated that 
MPV was higher in the patients with adverse outcomes and 
cardiac death during follow-up as compared to those without 
those. Moreover, elevated MPV was more useful for predicting 
cardiac death in those with ACS undergoing PCI. These findings 
are similar to our results apart from the fact that our cohort was 
only the patients who underwent elective PCI rather than PCI 
following newly diagnosed with ACS, urgent PCI. It seems that 
there is a difference between the outcomes of coronary inter-
vention after ACS and stable coronary artery disease. Due to 
these controversial findings and lack of sufficient investigations 
 r P
Platelet count -.0305 <0.001
PDW 0.615 <0.001
P-LCR 0.913 <0.001
Cholesterol 0.027 0.720
Triglyceride 0.053 0.484
LDL 0.073 0.329
HDL 0.122 0.103
Hematocrit, % 0.110 0.141
ALT, mg/dL 0.038 0.622
AST, mg/dL 0.060 0.430
Creatinine, mg/dL 0.102 0.172
ALT - alanine aminotransferase; AST - aspartate aminotransferase; HDL - high density 
lipoprotein; LDL - low density lipoprotein; PDW - platelet distribution width;  
P-LCR - platelet large-cell ratio
Table 2. Correlation analysis between mean platelet volume and other 
laboratory measurements
 OR 95% CI P*
Age 0.987 0.994-1.031 0.551
Gender, male 0.483 0.149-1.571 0.227
Body mass index 0.963 0.864-1.074 0.500
Diabetes mellitus 0.461 0.138-1.546 0.210
Dyslipidemia 1.906 0.725-5.013 0.191
Hypertension 0.723 0.266-1.961 0.524
Smoking 0.666 0.242-1.836 0.432
Familial history of CAD 1.671 0.594-4.700 0.331
LVEF 1.912 0.668-5.477 0.227
LAD 0.829 0.235-2.925 0.771
RCA 0.747 0.239-2.337 0.616
LCX 0.435 0.092-2.049 0.292
Platelet count 0.998 0.989-1.007 0.653
MPV level** 11.359 2.481-51.994 0.002
PDW 1.200 0.865-1.664 0.274
P-LCR 1.119 0.974-1.285 0.114
Hematocrit 1.126 0.976-1.299 0.104
Creatinine 4.325 0.455-41.103 0.202
*Logistic regression analysis 
**MPV level was considered as low-MPV <9.6 fL and high-MPV ≥9.6 fL 
CAD - coronary artery disease; CI - confidence interval; LAD - left anterior descending 
artery; LCX - left circumflex artery; LVEF - left ventricular ejection fraction;  
MPV - mean platelet volume; OR - odd ratio; PDW - platelet distribution width;  
P-LCR - platelet large-cell ratio; RCA - right coronary artery
Table 3. Odds ratios (OR) for incidence of major adverse cardiac 
events (MACE) by logistic regression analysis
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regarding this notion, it seems that further studies are needed 
to clarify it.
Prior studies’ findings are in accordance with our study show-
ing the independent predictor role of elevated MPV value for the 
incidence of MACE after PCI at 1-year follow-up period. Although, 
none of the cardiovascular risk factors were associated with ele-
vated MPV value except the LVEF subgroups which noted the more 
amount of LVEF <40% in the second compared with the first group.
Study limitations
This study suffered from some limitations based on its 
nature. First, our study was retrospective with a small sample 
size that might influence our findings for demonstrating more 
relations. Second, the blood samples analyzing was not the 
same for all patients and we could not definitely defined the 
duration of sample analyzing. Hence, probable delaying in mea-
surements might cause abnormal MPV values (20). Third, our 
cohort included those who underwent only elective PCI rather 
than the PCI following ACS, and therefore the rate of MACE was 
lower compared with previous similar studies. These findings 
indicate that further and large-scale studies are required to elu-
cidate the potential role of MPV in the patients undergoing PCI.
Conclusion
The result of this study suggests that MPV is an independent 
predictor of MACE at 1-year follow-up period in the patients 
undergoing elective PCI. Moreover, its value before PCI may be 
of benefit for risk stratification. Further prospective large-scale 
studies are needed to confirm our result.
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